BA
FATE icon

Boston Advisors’s Fate Therapeutics FATE Stock Holding History

Boston Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$997K Buy
64,186
+24,416
+61% +$468K 0.05% 387
2019
Q2 		$807K Hold
39,770
– – 0.04% 408
2019
Q1 		$699K Sell
39,770
-23,555
-37% -$372K 0.04% 409
2018
Q4 		$812K Buy
63,325
+6,565
+12% +$91.5K 0.05% 363
2018
Q3 		$925K Sell
56,760
-1,270
-2% -$15K 0.04% 391
2018
Q2 		$658K Buy
58,030
+6,570
+13% +$72.4K 0.02% 448
2018
Q1 		$502K Buy
+51,460
New +$493K 0.01% 495

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return

Boston Advisors's FATE Position: Q3 2019 in Review

Boston Advisors increased its Fate Therapeutics (FATE) stake by 61% in Q3 2019, buying an estimated $468K and bringing the position to 64,186 shares worth $997K. The position accounts for 0.05% of the portfolio, ranked #387.

Boston Advisors first reported a position in FATE in Q1 2018 and has held it in 7 quarters since. 149 funds tracked by Wall St. Rank hold FATE as of Q3 2019.

  • Boston Advisors held 64,186 shares of Fate Therapeutics worth $997K as of Q3 2019.
  • Boston Advisors bought 24,416 Fate Therapeutics shares in Q3 2019, an estimated $468K.
  • Fate Therapeutics made up 0.05% of Boston Advisors's portfolio in Q3 2019, its #387 holding.
  • Boston Advisors first reported a position in Fate Therapeutics in Q1 2018 and has held it in 7 quarters since.
  • 149 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2019.

Based on Boston Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.